Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Senseonics Q1 2026 Earnings Call - Revenue Surges 85% as Commercial Integration Drives Margin Expansion
Senseonics delivered a robust Q1 2026, reporting $11.7 million in revenue, an 85% year-over-year increase, and a 58% gross margin. The company successfully integrated its U.S. commercial organization ...
- Q1 2026 revenue reached $11.7 million, an 85% year-over-year increase, driven by strong Eversense 365 adoption and a favorable shift toward higher-margin bundled reimbursement channels.
- Gross margin expanded to 58%, reflecting higher average selling prices, increased manufacturing volumes, and the structural benefit of eliminating the Ascensia revenue share.
- Senseonics raised its full-year 2026 global net revenue guidance to $60-$64 million, representing 70-82% year-over-year growth, up from the previous range of $58-$62 million.
- +12 more takeaways
Full House Resorts Q1 2026 Earnings Call - Construction Financing Nears Completion as Marketing Shifts Drive Colorado Revenue Growth
Full House Resorts reported a solid first quarter with revenues of $74.4 million and adjusted EBITDA rising 15% to $13.2 million, driven by strong performance at American Place and cost discipline acr...
- Revenues of $74.4 million in Q1 2026, down slightly from $75.1 million in Q1 2025, but up 0.9% on an apples-to-apples basis after excluding Stockman’s revenue.
- Adjusted EBITDA rose 15% to $13.2 million, up from $11.5 million in Q1 2025, reflecting strong profitability improvements.
- American Place temporary casino drove 7% revenue growth to $31.8 million, with adjusted property EBITDA up 8% to $8.3 million, despite a 1.2 percentage point decline in table games hold.
- +7 more takeaways
BILL Q3 2026 Earnings Call - AI-Native Pivot and 30% Workforce Reduction Signal a New Era
BILL delivered a quarter of decisive structural change. Core revenue grew 16% to $371 million, while non-GAAP operating margin expanded sharply to 20% and the company achieved GAAP profitability. Mana...
- Core revenue grew 16% year-over-year to $371 million, extending a strong trajectory of durable growth.
- Non-GAAP operating margin reached 20%, expanding 475 basis points year-over-year and surpassing guidance.
- BILL achieved GAAP profitability for the first time, signaling a shift toward sustained earnings generation.
- +12 more takeaways
Arcturus Therapeutics Q1 2026 Earnings Call - Inhaled mRNA CF Program Achieves Unprecedented Tolerability Beyond One Month
Arcturus Therapeutics delivered a quarter defined by clinical momentum and strategic refocusing. The company initiated its 12-week open-label Phase II study for ARCT-032, its inhaled mRNA candidate fo...
- Arcturus initiated a 12-week open-label Phase II study for ARCT-032 in Class 1 cystic fibrosis patients, a critical step for an inhaled mRNA therapy.
- Management highlighted that continuous dosing beyond one month has never been successfully tolerated with inhaled mRNA therapeutics, a key differentiator for their platform.
- The company is evaluating lung function metrics including percent predicted FEV1 and lung clearance index (LCI) to assess early clinical benefit.
- +7 more takeaways
Fox Factory Holding Corp Q1 2026 Earnings Call - Cost Cuts Offset Tariffs as Management Reaffirms 2026 Outlook
Fox Factory delivered Q1 revenue of $368.7 million, hitting the high end of guidance, while adjusted EBITDA of $35.7 million beat expectations. Management is reaffirming its full-year 2026 outlook, ex...
- Q1 revenue of $368.7 million hit the high end of guidance, while adjusted EBITDA of $35.7 million exceeded expectations.
- Management reaffirmed full-year 2026 guidance, expecting net sales between $1.328 billion and $1.416 billion and adjusted EBITDA between $174 million and $203 million.
- The company is executing on a $50 million cost-saving initiative, with $10 million in carryover and $40 million in new phase 2 actions.
- +7 more takeaways
Profound Medical Q1 2026 Earnings Call - First Formal Guidance Set as TULSA Platform Gains Reimbursement Traction
Profound Medical delivered a decisive Q1 2026 quarter, flipping revenue growth into sharper losses while locking in its first formal full-year guidance of CAD 25 million. The company’s TULSA platform ...
- Revenue surged 104% year-over-year to CAD 5.3 million, driven by a mix of CAD 2.9 million in capital equipment sales and CAD 2.5 million in recurring revenue.
- Net loss narrowed sharply to CAD 7 million from CAD 10.7 million a year ago, with operating expenses falling 9% to CAD 11.8 million as the company scales.
- Gross margin expanded to 72% from 71% in Q1 2025, primarily due to a favorable product mix favoring higher-margin capital equipment sales.
- +7 more takeaways
Forward Air Q1 2026 Earnings Call - Strategic Pivot Amid Customer Diversification and Intermodal Sale
Forward Air reported a solid Q1 2026 with operating income of $20M and consolidated EBITDA of $70M, demonstrating margin stability across its core Expedited and Omni Logistics segments. However, the c...
- Operating income improved to $20 million in Q1 2026, up from $5 million in Q1 2025, while consolidated EBITDA was $70 million, slightly down from $73 million a year ago.
- Expedited Freight segment EBITDA rose to $28 million from $26 million year-over-year, maintaining a stable 10.4% margin.
- Omni Logistics segment EBITDA remained flat at $25 million, with margins improving to 7.9% from 8.3% due to a mix shift toward higher-margin contract logistics.
- +10 more takeaways
Sensus Healthcare Q1 2026 Earnings Call - New CPT Codes Drive Recurring Revenue Pivot
Sensus Healthcare reported a sharp revenue decline to $3.4 million in Q1 2026, a direct consequence of shedding its reliance on a single large customer that accounted for $5.6 million in the prior yea...
- Revenue fell to $3.4 million from $8.3 million year-over-year, primarily due to zero sales to a historically large customer that contributed $5.6 million in Q1 2025.
- Excluding the large customer, underlying revenue grew to $3.4 million from $2.7 million, signaling organic demand across a more diversified base.
- Dedicated CPT codes for superficial radiotherapy, effective January 1, 2026, have eliminated reimbursement uncertainty and driven a 300% increase in per-fraction payment rates.
- +7 more takeaways
Gevo Inc Q1 2026 Earnings Call - Strong EBITDA Growth and Project North Star Financing Shift to Private Capital
Gevo delivered a solid first quarter 2026, reporting $43 million in revenue and $9 million in non-GAAP adjusted EBITDA, a sharp turnaround from a $15 million loss in the prior year quarter. The compan...
- Gevo reported Q1 2026 revenue of $43 million, up from $29 million in Q1 2025, driven by strong production and margin performance in low carbon ethanol and carbon attributes.
- Non-GAAP adjusted EBITDA reached $9 million in Q1 2026, a significant improvement from a $15 million loss in the prior year quarter, despite including $11 million in debt extinguishment costs.
- The company reaffirmed its 2026 adjusted EBITDA target of $30 million and its goal to reach a $40 million annualized run rate from existing operations by year-end.
- +7 more takeaways
DXP Enterprises Q1 2026 Earnings Call - Strong Margin Expansion and Backlog Growth Offset Soft January
DXP Enterprises delivered a sluggish start to 2026 with a weak January, but the momentum reversed sharply in February and March, driving a 9.5% year-over-year sales increase to $521.7 million. The com...
- Sales grew 9.5% year-over-year to $521.7 million, with average daily sales accelerating from $7.2 million in January to $9.2 million in March.
- Gross profit margins expanded 79 basis points year-over-year to 32.3%, driven by pricing discipline, favorable product mix, and higher-margin acquisitions.
- Adjusted EBITDA reached $57.8 million, maintaining an 11.1% margin despite seasonal SG&A headwinds and discrete acquisition-related costs.
- +7 more takeaways